Company Overview - Proactive is a financial news publisher that provides fast, accessible, informative, and actionable business and finance news content to a global investment audience [2] - The company has a team of experienced news journalists who produce independent content across various financial markets [2] Market Focus - Proactive specializes in medium and small-cap markets while also covering blue-chip companies, commodities, and broader investment stories [3] - The content delivered includes insights across sectors such as biotech and pharma, mining and natural resources, battery metals, oil and gas, crypto, and emerging digital and EV technologies [3] Technology Adoption - Proactive is recognized for its forward-looking approach and enthusiastic adoption of technology to enhance workflows [4] - The company utilizes automation and software tools, including generative AI, while ensuring that all content is edited and authored by humans [5]

About this content About Emily Jarvie Emily began her career as a political journalist for Australian Community Media in Hobart, Tasmania. After she relocated to Toronto, Canada, she reported on business, legal, and scientific developments in the emerging psychedelics sector before joining Proactive in 2022. She brings a strong journalism background with her work featured in newspapers, magazines, and digital publications across Australia, Europe, and North America, including The Examiner, The Advocate, ...

Harmony Biosciences (HRMY) Conference July 17, 2025 10:00 AM ET Speaker0Good morning, everyone, and welcome to HC Wainwright at Home, our virtual fireside chat series. I'm Patrick Trucchio, a senior health care analyst at HCW. Today, we're joined by Jeffrey Dano, president and chief executive officer Kumar Boudur, Chief Medical and Scientific Officer Sandeep Tapadia, Chief Financial Officer and Adam Zeski, Chief Commercial Officer of Harmony Biosciences. Harmony's commercial franchise is anchored by Wakix o ...

Group 1 - Proactive provides fast, accessible, informative, and actionable business and finance news content to a global investment audience [2] - The news team covers medium and small-cap markets, as well as blue-chip companies, commodities, and broader investment stories [3] - Proactive's content includes insights across various sectors such as biotech, pharma, mining, natural resources, battery metals, oil and gas, crypto, and emerging technologies [3] Group 2 - Proactive is committed to adopting technology to enhance workflows and content production [4] - The company utilizes automation and software tools, including generative AI, while ensuring all content is edited and authored by humans [5]

CANADA - 2025/05/11: In this photo illustration, the Rigetti Computing logo is seen displayed on a ... More smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images) SOPA Images/LightRocket via Getty Images Rigetti Computing's stock jumped 30% on July 16 after reaching 99.5% gate fidelity on its 36-qubit modular system—halving error rates compared to its earlier 84-qubit chip. This achievement confirms their chiplet-based architecture as a scalable option for practica ...

PHOENIX, July 17, 2025 (GLOBE NEWSWIRE) -- Creative Medical Technology Holdings, Inc. (NASDAQ: CELZ) (“Creative Medical” or the “Company”), a clinical-stage biotechnology company specializing in regenerative medicine, today announced that it has received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for a U.S. patent application titled, “Prevention and/or Treatment of Type 1 Diabetes by Augmentation of Myeloid Suppressor Cell Activity.” Once granted, the patent will be in ...

About this content About Emily Jarvie Emily began her career as a political journalist for Australian Community Media in Hobart, Tasmania. After she relocated to Toronto, Canada, she reported on business, legal, and scientific developments in the emerging psychedelics sector before joining Proactive in 2022. She brings a strong journalism background with her work featured in newspapers, magazines, and digital publications across Australia, Europe, and North America, including The Examiner, The Advocate, ...

NEW YORK, July 17, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Sarepta Therapeutics, Inc. (NASDAQ: SRPT).Shareholders who purchased shares of SRPT during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.CONTACT US HERE: https://securitiesclasslaw.com/securities/sarepta-loss-submission-form/?id=156859&from=4 CLASS PERIOD: June 22, 2023 to ...

Ambitious study will profile thousands of tumor samples to uncover novel biomarkers and therapeutic targets for cancer and inflammatory diseasesPLEASANTON, Calif. and SINGAPORE, July 17, 2025 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, and the A*STAR Genome Institute of Singapore (A*STAR GIS), today announced a research collaboration for the Target Inference from Spatialomics & Histology Using Multimodal AI & Phenotypes (TISHUMAP) project. This initiative w ...

Core Insights - Fifty1 AI Labs, LLC has announced a strategic partnership with the intent to acquire BioSpark AI Technologies Inc., aiming to revolutionize drug repurposing through advanced AI technologies [1][4] - The collaboration will integrate BioSpark's AI and large language model (LLM) platform with Fifty1 AI Labs' predictive modeling to enhance the analysis of extensive medical literature [2][3] Group 1: Partnership and Acquisition - The partnership is designed to leverage AI to extract transformative insights from medical literature, thereby advancing functional medicine and preventative care [1][4] - Fifty1 AI Labs intends to fully acquire BioSpark, which will enhance its capabilities in identifying promising drug repurposing candidates [3][4] Group 2: Technological Integration - BioSpark's proprietary AI platform automates the extraction and structuring of clinical data, which will significantly improve the efficiency of identifying therapeutic patterns [2][3] - The integration of BioSpark's capabilities with Fifty1 AI Labs' Bayesian inference and polypharmacy modeling will create a new approach to drug repurposing based on real-world clinical data [3][4] Group 3: Strategic Vision - The alliance aims to dominate preventative healthcare through personalized, data-driven strategies and rapid identification of drug candidates [4][5] - Both companies share a commitment to enhancing human expertise with ethical AI tools, focusing on opportunities in functional medicine that traditional trials may overlook [5][6] Group 4: Company Background - BioSpark AI Technologies Inc. specializes in organizing real-world clinical data using proprietary AI and LLM technologies and holds a U.S. patent for its automation system [6] - Fifty1 AI Labs, a subsidiary of Fifty 1 Labs, Inc., focuses on AI-driven functional medicine, addressing critical needs in performance health and chronic disease prevention [7][8]